Genomed SA
WSE:GEN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25
33.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Genomed SA
Total Current Assets
Genomed SA
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genomed SA
WSE:GEN
|
Total Current Assets
zł9.4m
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
M
|
Mabion SA
WSE:MAB
|
Total Current Assets
zł59.3m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
R
|
Read Gene SA
WSE:RDG
|
Total Current Assets
zł5.2m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
20%
|
|
|
B
|
Bioton SA
WSE:BIO
|
Total Current Assets
zł150.7m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-8%
|
|
|
U
|
Urteste SA
WSE:URT
|
Total Current Assets
zł26.5m
|
CAGR 3-Years
248%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Synthaverse SA
WSE:SVE
|
Total Current Assets
zł44.1m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-4%
|
|
Genomed SA
Glance View
Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.
See Also
What is Genomed SA's Total Current Assets?
Total Current Assets
9.4m
PLN
Based on the financial report for Dec 31, 2023, Genomed SA's Total Current Assets amounts to 9.4m PLN.
What is Genomed SA's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
8%
Over the last year, the Total Current Assets growth was 30%. The average annual Total Current Assets growth rates for Genomed SA have been 9% over the past three years , 8% over the past five years .
You don't have any saved screeners yet
